No Data
Sichuan Kelun Pharmaceutical (002422.SZ): Amara intends to increase its shareholding of the company by 50 million to -99 million yuan.
On February 28, Gelonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) announced that it recently received a notification from a shareholder holding more than 5%, Amara State-owned Assets Operation Co., Ltd. (referred to as 'Amara State-owned Assets Company'), which plans to increase its shareholding in the company within six months from the date of announcement through methods permitted by the Shenzhen Stock Exchange (the planned purchase price does not exceed 37.60 yuan/share). The amount of this increase will be no less than 50 million yuan (including principal) and no more than 99 million yuan (including principal), with the specific total funding amount for the purchase to be based on the actual funds used.
Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Shares Could Be 46% Below Their Intrinsic Value Estimate
Sichuan Kelun Pharmaceutical (002422.SZ): Research results of lucanib and trastuzumab (SAC-TMT) will be announced at the 2025 ASCO GU Cancer Symposium.
Sichuan Kelun Pharmaceutical (002422.SZ) announced that the company recently learned that its controlling subsidiary, Kelun Botai Life...
Kelun Pharmaceutical Gets Chinese Drug Registration for Antibiotic
Sichuan Kelun Pharmaceutical (002422.SZ): Rituximab N01 injection has been approved for market launch.
Sichuan Kelun Pharmaceutical (002422.SZ) announced that its controlling subsidiary SiChuan Kelun Botai Biomedical Co., Ltd...
Guolian: Structural differentiation in the Industry may further intensify, and companies that lead in Innovative Drugs and international layout are likely to continue to take the lead.
In addition, the proportion of the CSI SWS Health Care index Public Fund in Q4 2024 is at a historic low since 2010, suggesting a focus on companies with positive earnings expectations for 2024.
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
